RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.

Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.

Updates are delayed or unverified. Check original sources for the latest information.

Your saved research and appointment questions

View recorded trial and retraction changes

ICD G36.0ORPHA:71211NMOSD

Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica Spectrum Disorder is a rare autoimmune disease of the central nervous system that primarily attacks the optic nerves and spinal cord. It is frequently misdiagnosed as Multiple Sclerosis. The majority of cases involve antibodies against aquaporin-4 (AQP4) water channels. Timely diagnosis is critical as some MS treatments can worsen NMOSD.

This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.

1,110
Articles
101
Trials (4 AU)
Data refreshed
19 October 2026
Loading...

Common Questions

What is Neuromyelitis Optica Spectrum Disorder?

Neuromyelitis Optica Spectrum Disorder is a rare autoimmune disease of the central nervous system that primarily attacks the optic nerves and spinal cord. It is frequently misdiagnosed as Multiple Sclerosis. The majority of cases involve antibodies against aquaporin-4 (AQP4) water channels. Timely diagnosis is critical as some MS treatments can worsen NMOSD.

How many clinical trials are available for Neuromyelitis Optica Spectrum Disorder?

RareWays currently indexes 101 clinical trials for Neuromyelitis Optica Spectrum Disorder, of which 21 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.

Where does the research data for Neuromyelitis Optica Spectrum Disorder come from?

RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.

Get research updates

Monthly email when new findings are published for Neuromyelitis Optica Spectrum Disorder.

Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.

This information is for general awareness only.

For guidance specific to your situation, please speak with your healthcare team.